HIV-1潜伏库调控剂的研究进展  

Advances in HIV-1 latency-regulating agents

作　　者：代娇娇 姜向毅 封达 林浩 刘新泳[1] 展鹏[1] DAI Jiao-jiao;JIANG Xiang-yi;FENG Da;LIN Hao;LIU Xin-yong;ZHAN Peng(Department of Medicinal Chemistry,Key laboratory of Chemical Biology(Ministry of Education),School of Pharmaceutical Sciences,Shandong University,Jinan 250012,China)

机构地区：[1]山东大学药学院药物化学研究所,化学生物学教育部重点实验室,山东济南250012

出　　处：《药学学报》2024年第4期840-852,共13页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金国际(地区)合作与交流项目(82211530493);国家自然科学基金面上项目(82173677);山东省杰出青年基金(ZR2020JQ31)。

摘　　要：HIV-1潜伏库的存在导致艾滋病无法彻底治愈。因此,迫切需要开发高效低毒、成药性良好的HIV-1潜伏库调控剂以实现艾滋病的功能性治愈。本文综述了2019年以来潜伏库调控剂的研究进展,涵盖药物发现策略、生物活性和作用机制。本文对于发现具有临床应用价值的HIV-1潜伏库调控剂具有重要的指导意义。At present,there is no cure for acquired immune deficiency syndrome(AIDS)due to HIV-1 latent reservoirs.Therefore,it urgently requires novel HIV-1 latency-regulating agents with high potency,low toxicity and favorable drug-like properties to achieve a functional cure for AIDS.Herein,we reviewed the advances in HIV-1 latency-regulating agents since 2019,including the drug discovery strategies,bioactivities,and mechanisms of these compounds.It is of great guiding significance in the development of latency-regulating agents with clinical value.

关 键 词：艾滋病 HIV-1潜伏库 功能性治愈 激活并杀死 阻滞并锁定 

分 类 号：R914[医药卫生—药物化学]